Please login to the form below

Not currently logged in
Email:
Password:

Eisai sets up new pharmaceutical marketing subsidiary in Belgium

Japanese pharmaceutical company, Eisai, has established its pharmaceutical marketing subsidiary, Eisai SA/NV in Belgium.

Japanese pharmaceutical company, Eisai, has established its pharmaceutical marketing subsidiary, Eisai SA/NV in Belgium.

Eisai SA/NV is owned by Eisai Europe and will serve as the regional sales centre for Benelux countries, the sixth largest market in the EU. The subsidiary will begin marketing activities in the region, focusing on the anti-epileptic drugs Zonegran (zonisamide) and Inovelon (rufinamide). It will also start to market the non-opioid severe chronic infused pain drug Prialt (ziconotide), while also co-promoting Alzheimer's disease treatment Aricept (donepezil) in Belgium and Luxembourg with its partner, Pfizer.

Eisai says it will further expand its business operations across the EU and will undertake independent marketing activities by using its own sales and marketing personnel, tailored for each county.

Eisai SA/NV is Eisai's ninth marketing subsidiary in the EU region, bringing the total number of countries where Eisai has sales and marketing operations through its own distribution channels to 17. These include the UK, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Belgium, Netherlands and Luxembourg.



28th September 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics